These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2013-001033-40 A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma 2015-12-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-002405-61 A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2020-12-23 bad-data
Reported results 2013-003639-31 A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 2020-06-12 due-trials
Reported results 2013-004008-20 A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma. 2020-11-05 due-trials
Not reported 2016-000848-34 Long term, Continued Treatment and Follow up Study in Subjects with Hematologic Malignancies Treated with Duvelisib (IPI 145) Studio a lungo termine di continuazione del trattamento e follow-up in ... 2020-05-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-001123-13 A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) 2023-12-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2019-001381-14 A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL) 2023-07-24 bad-data
Other 2020-004264-26 A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201) not-yet-due
Reported results Terminated 2020-004265-39 A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC) Estudi... 2023-12-12 due-trials